JP2024109911A5 - - Google Patents

Download PDF

Info

Publication number
JP2024109911A5
JP2024109911A5 JP2024086951A JP2024086951A JP2024109911A5 JP 2024109911 A5 JP2024109911 A5 JP 2024109911A5 JP 2024086951 A JP2024086951 A JP 2024086951A JP 2024086951 A JP2024086951 A JP 2024086951A JP 2024109911 A5 JP2024109911 A5 JP 2024109911A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
arm
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024086951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024109911A (ja
Filing date
Publication date
Priority claimed from JP2021525728A external-priority patent/JP7497351B2/ja
Application filed filed Critical
Publication of JP2024109911A publication Critical patent/JP2024109911A/ja
Publication of JP2024109911A5 publication Critical patent/JP2024109911A5/ja
Pending legal-status Critical Current

Links

JP2024086951A 2018-11-13 2024-05-29 チェックポイント分子に対する多重特異性結合性構築物およびその使用 Pending JP2024109911A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862760801P 2018-11-13 2018-11-13
US62/760,801 2018-11-13
US201962855580P 2019-05-31 2019-05-31
US62/855,580 2019-05-31
US201962898991P 2019-09-11 2019-09-11
US62/898,991 2019-09-11
US201962931478P 2019-11-06 2019-11-06
US62/931,478 2019-11-06
JP2021525728A JP7497351B2 (ja) 2018-11-13 2019-11-13 チェックポイント分子に対する多重特異性結合性構築物およびその使用
PCT/US2019/061226 WO2020102387A1 (en) 2018-11-13 2019-11-13 Multispecific binding constructs against checkpoint molecules and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021525728A Division JP7497351B2 (ja) 2018-11-13 2019-11-13 チェックポイント分子に対する多重特異性結合性構築物およびその使用

Publications (2)

Publication Number Publication Date
JP2024109911A JP2024109911A (ja) 2024-08-14
JP2024109911A5 true JP2024109911A5 (enExample) 2024-12-24

Family

ID=70731958

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525728A Active JP7497351B2 (ja) 2018-11-13 2019-11-13 チェックポイント分子に対する多重特異性結合性構築物およびその使用
JP2024086951A Pending JP2024109911A (ja) 2018-11-13 2024-05-29 チェックポイント分子に対する多重特異性結合性構築物およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021525728A Active JP7497351B2 (ja) 2018-11-13 2019-11-13 チェックポイント分子に対する多重特異性結合性構築物およびその使用

Country Status (13)

Country Link
US (2) US11046769B2 (enExample)
EP (1) EP3880716A4 (enExample)
JP (2) JP7497351B2 (enExample)
KR (1) KR20210107628A (enExample)
CN (2) CN119735694A (enExample)
AU (1) AU2019379576A1 (enExample)
BR (1) BR112021008795A2 (enExample)
CA (1) CA3119161A1 (enExample)
IL (1) IL283087A (enExample)
MX (3) MX2021005594A (enExample)
SG (1) SG11202104864QA (enExample)
TW (1) TWI840442B (enExample)
WO (1) WO2020102387A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226984A1 (zh) * 2020-05-15 2021-11-18 三生国健药业(上海)股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
CN113754773A (zh) * 2020-06-02 2021-12-07 三生国健药业(上海)股份有限公司 一种抗pd1×pdl1的双特异性抗体
EP4314062A1 (en) * 2021-03-31 2024-02-07 Merus N.V. Novel pd-1 binding domains
CN118974094A (zh) * 2022-04-08 2024-11-15 江苏济烨生物制药有限公司 一种抗原结合蛋白及其应用
CN116574192A (zh) * 2023-03-30 2023-08-11 上海妙聚生物科技有限公司 一种可条件性释放并激活的细胞因子融合蛋白及其制备和用途

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4496654A (en) 1983-04-08 1985-01-29 Quidel Detection of HCG with solid phase support having avidin coating
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5026773A (en) 1987-03-11 1991-06-25 Samuel Steel Apparatus for a solid phase synthesis of peptide analogs
JPH021556A (ja) 1988-06-09 1990-01-05 Snow Brand Milk Prod Co Ltd ハイブリッド抗体及びその作製方法
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5071909A (en) 1989-07-26 1991-12-10 Millipore Corporation Immobilization of proteins and peptides on insoluble supports
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
ES2336444T3 (es) 1990-02-01 2010-04-13 Siemens Healthcare Diagnostics Products Gmbh Obtencion y empleo de ginotecas de anticuerpos humanos ("bancos de anticuerpos humanos").
CZ280777B6 (cs) 1990-02-02 1996-04-17 Ústav Organické Chemie A Biochemie Avčr Mnohonásobná automatizovaná syntéza peptidů na planárních nosičích
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
EP1471142B1 (en) 1991-04-10 2008-11-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DE69318016D1 (de) 1992-05-08 1998-05-20 Creative Biomolecules Inc Mehrwertige Chimäre Proteine Anologe und Verfahren zu deren Anwendungen
US5287082A (en) 1992-07-02 1994-02-15 Cornell Research Foundation, Inc. Submicron isolated, released resistor structure
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP1550729B1 (en) 1992-09-25 2009-05-27 Avipep Pty Limited Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
GB9323648D0 (en) 1992-11-23 1994-01-05 Zeneca Ltd Proteins
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
WO1996013583A2 (en) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Targeted hetero-association of recombinant proteins to multi-functional complexes
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
JP2000508892A (ja) 1996-04-04 2000-07-18 ユニリーバー・ナームローゼ・ベンノートシャープ 多価および多特異的抗原結合タンパク
WO1997042217A1 (en) 1996-05-06 1997-11-13 The Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
CA2288994C (en) 1997-04-30 2011-07-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE69827507T2 (de) 1997-06-11 2006-03-09 Borean Pharma A/S Trimerisierendes modul
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
ES2234241T3 (es) 1998-01-23 2005-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Derivados de anticuerpo de multiples fines.
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
AU784062B2 (en) 1999-08-23 2006-01-19 Dana-Farber Cancer Institute, Inc. Novel B7-4 molecules and uses therefor
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
CA2417185A1 (en) 2000-07-25 2002-01-31 Shui-On Leung Multivalent target binding protein
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
EP2351838A1 (en) 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Crosslinking agonistic antibodies
EP1360288B1 (en) 2000-12-18 2011-02-16 Dyax Corp. Focused libraries of genetic packages
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2002072635A2 (en) 2001-03-13 2002-09-19 University College London Specific binding members
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
ES2276735T3 (es) 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
AU2002357072A1 (en) 2001-12-07 2003-06-23 Centocor, Inc. Pseudo-antibody constructs
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
EP1487879B1 (en) 2002-03-01 2012-12-26 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
ATE531796T1 (de) 2002-03-21 2011-11-15 Sangamo Biosciences Inc Verfahren und zusammensetzungen zur verwendung von zinkfinger-endonukleasen zur verbesserung der homologen rekombination
AU2003227504A1 (en) 2002-04-15 2003-10-27 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
WO2003104415A2 (en) 2002-06-05 2003-12-18 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
AU2003298574B2 (en) 2002-09-05 2008-04-24 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
CA2522819A1 (en) 2003-04-22 2004-11-04 Immunomedics, Inc. Polyvalent protein complex
AU2004252171B2 (en) 2003-06-27 2011-04-21 Biogen Ma Inc. Modified binding molecules comprising connecting peptides
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
EP1697748A4 (en) 2003-12-22 2007-07-04 Centocor Inc METHODS FOR GENERATING MULTIMEDIA MOLECULES
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US7557197B2 (en) 2004-01-28 2009-07-07 Oregon Health & Science University Human soluble neuropilin-1 primary polyadenylation signal and uses thereof
US8383575B2 (en) 2004-01-30 2013-02-26 Paul Scherrer Institut (DI)barnase-barstar complexes
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
DK2330121T3 (en) 2004-06-02 2014-12-15 Adalta Pty Ltd Binding moieties based on shark IgNar domains
WO2006020258A2 (en) 2004-07-17 2006-02-23 Imclone Systems Incorporated Novel tetravalent bispecific antibody
US20060040354A1 (en) 2004-07-20 2006-02-23 O'keefe Theresa L Novel polyadenylation signal for use in expression vectors
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
WO2006084050A2 (en) 2005-02-01 2006-08-10 Dyax Corp. Libraries and methods for isolating antibodies
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
CN101484182B (zh) 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディとその使用
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
KR101419729B1 (ko) 2005-07-26 2014-07-17 상가모 바이오사이언스 인코포레이티드 외래 핵산 서열의 표적화된 통합 및 발현
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DE602005018477D1 (de) 2005-08-26 2010-02-04 Pls Design Gmbh Bivalente IgY Antikörperkonstrukte für diagnostische und therapeutische Anwendungen
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
CN101331223A (zh) 2005-10-14 2008-12-24 米迪缪尼有限公司 细胞展示抗体文库
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
WO2007062466A1 (en) 2005-11-29 2007-06-07 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
JP2009526857A (ja) 2006-02-15 2009-07-23 イムクローン・リミテッド・ライアビリティ・カンパニー 機能性抗体
SG170750A1 (en) 2006-03-17 2011-05-30 Biogen Idec Inc Stabilized polypeptide compositions
WO2007108152A1 (ja) 2006-03-23 2007-09-27 Tohoku University 高機能性二重特異性抗体
US8946391B2 (en) 2006-03-24 2015-02-03 The Regents Of The University Of California Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP2027153B1 (en) 2006-05-25 2014-04-30 Bayer Intellectual Property GmbH Dimeric molecular complexes
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
BRPI0716680A2 (pt) 2006-11-02 2013-09-24 Daniel J Capon "composto, multÍmero, composiÇço, mÉtodo de afetar a atividade de um alvo, complexo, processo de produÇço do composto, mÉtodo de produÇço de um extensço de aminoÁcidos consecutivos, processo de produÇço de uma extensço de aminoacidos consecutivos , processo para a produÇço de um composto , mÉtodo de produÇço de uma proteina e polipeptÍdeo"
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
CA2696263C (en) 2007-08-15 2017-06-13 Bing Liu Monospecific and multispecific antibodies and method of use
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN101855242B (zh) 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
US7947495B2 (en) 2007-11-01 2011-05-24 Abbott Biotherapeutics Corp. Immunoglobulin display vectors
CA2706200A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs comprising multiple single variable domains and an fc portion
EP2615115A3 (en) 2007-11-30 2014-01-08 Glaxo Group Limited Antigen-binding constructs
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
WO2009089295A2 (en) 2008-01-07 2009-07-16 Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Anti-hiv domain antibodies and method of making and using same
DE102008010362A1 (de) 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen
AU2009240481B2 (en) 2008-04-24 2015-07-30 Takeda Pharmaceutical Company Limited Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
WO2010028791A1 (en) 2008-09-10 2010-03-18 Philochem Ag Display library for antibody selection
MX2011003195A (es) * 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
US8217149B2 (en) * 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
BR122015012748A2 (pt) 2009-07-17 2020-01-07 Bioatla, Llc Métodos de evolução, identificação e produção de uma proteína
MX2012003396A (es) 2009-09-16 2012-04-10 Genentech Inc Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
EP3336225B1 (en) 2010-07-16 2020-02-19 Adimab, LLC Antibody libraries
CN102760801B (zh) 2011-04-29 2015-04-01 清华大学 发光二极管的制备方法
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
DK2771364T3 (da) 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
ES2848052T3 (es) 2012-08-03 2021-08-05 Dana Farber Cancer Inst Inc Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso
CA3201072A1 (en) * 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
MX378463B (es) 2013-02-26 2025-03-10 Memorial Sloan Kettering Cancer Center Composiciones y usos de las mismas para inmunoterapia.
SG11201600310QA (en) 2013-07-16 2016-02-26 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
DK3089994T3 (da) 2013-12-30 2022-07-04 Epimab Biotherapeutics Inc Fabs-in-tandem-immunglobulin og anvendelser deraf
EP3092004A4 (en) 2014-01-06 2017-02-22 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
EP3094650A2 (en) 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
EP3149042B1 (en) 2014-05-29 2019-08-28 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
RU2722212C9 (ru) 2014-08-05 2020-07-23 СиБи ТЕРЕПЬЮТИКС, ИНК. Анти-pd-l1 антитела
SG11201701039PA (en) 2014-08-14 2017-03-30 Hoffmann La Roche Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
US20170247455A1 (en) 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2016030455A1 (en) 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
CA2964367C (en) * 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
AU2016206707A1 (en) 2015-01-14 2017-08-10 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
JP6826055B2 (ja) * 2015-03-13 2021-02-03 サイトメックス セラピューティクス インコーポレイテッド 抗pdl1抗体、活性化可能抗pdl1抗体、およびその使用方法
ES2813580T3 (es) 2015-04-17 2021-03-24 Bristol Myers Squibb Co Composiciones que comprenden una combinación de ipilimumab y nivolumab
EP3313186A4 (en) 2015-06-29 2019-04-03 Biomed Valley Discoveries, Inc. LPT-723 AND IMMUNE CONTROL POINT COMBINATIONS AND TREATMENT PROCEDURES
US20180251548A1 (en) 2015-09-14 2018-09-06 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-beta
EP3359568B1 (en) 2015-10-07 2022-03-09 F. Hoffmann-La Roche AG Bispecific antibodies with tetravalency for a costimulatory tnf receptor
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017124002A1 (en) 2016-01-13 2017-07-20 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
RU2767329C2 (ru) 2016-02-06 2022-03-17 Эпимаб Биотерапьютикс, Инк. Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
CN118185874A (zh) 2016-04-04 2024-06-14 苏黎世联邦理工学院 一种重组哺乳动物b细胞
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
SG11201811003PA (en) 2016-06-13 2019-01-30 I Mab Anti-pd-l1 antibodies and uses thereof
WO2017220989A1 (en) * 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
BR112018076684A2 (pt) * 2016-06-29 2019-04-02 Checkpoint Therapeutics, Inc anticorpos pd-l1 específicos e métodos de uso dos mesmos
IL322509A (en) * 2017-03-09 2025-10-01 Genmab As Antibodies against PD-L1
EP3608341A4 (en) * 2017-04-01 2021-01-06 Beijing Hanmi Pharmaceutical Co., Ltd. HETERODIMER BIS SPECIFIC ANTI-PD-1 / ANTI-HER2 ANTIBODIES WITH NATURAL ANTIBODY STRUCTURE AND PRODUCTION OF IT
WO2018195226A1 (en) * 2017-04-18 2018-10-25 R-Pharm Overseas, Inc. Anti-pd-l1 antibody and use thereof
EA202090003A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
WO2020006605A1 (en) 2018-07-04 2020-01-09 Honeycomb Media Pty Ltd Method and system for providing incentives to users

Similar Documents

Publication Publication Date Title
JP2024109911A5 (enExample)
JP2018108081A5 (enExample)
JP2023129543A5 (enExample)
IL302078A (en) Anti-ccr8 monoclonal antibodies and uses thereof
JP2022061992A5 (enExample)
JP2025111463A5 (enExample)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2024150751A5 (enExample)
FI4045533T3 (fi) Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
JP2018035138A5 (enExample)
JP2013056885A5 (enExample)
JP2024167313A5 (enExample)
JP2018521638A5 (enExample)
JP2023071956A5 (enExample)
JP2020500538A5 (enExample)
JP2020516240A5 (enExample)
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
JP2020537520A5 (enExample)
JP2013529183A5 (enExample)
JP2010524435A5 (enExample)
HRP20201503T1 (hr) MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79
HRP20160584T1 (hr) Novo anti-dr5 antitijelo
JP2025032102A5 (enExample)
JP2017529838A5 (enExample)